Compounds > cgp 6809
Page last updated: 2024-12-08

cgp 6809

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Cross-References

ID SourceID
PubMed CID163402
SCHEMBL ID11226054
MeSH IDM0109655

Synonyms (10)

Synonym
cgp 6809
84069-38-5
3-[(2r)-2-[(2r,3r,4r,5s)-5-ethoxy-4-hydroxy-3-methoxyoxolan-2-yl]-2-methoxyethyl]-1-methyl-1-nitrosourea
cgp-6809
ethyl-6-deoxy-3,5-di-o-methyl-6-(3-methyl-3-nitrosoureido)glucofuranoside
SCHEMBL11226054
DTXSID701004355
ethyl 6-deoxy-6-({hydroxy[methyl(nitroso)amino]methylidene}amino)-3,5-di-o-methylhexofuranoside
PD162081
AKOS040751115

Research Excerpts

Overview

CGP 6809 is a water-soluble nitrosourea derivative. It is a promising new agent for clinical trials, especially for large bowel and epidermoid lung cancer.

ExcerptReferenceRelevance
"CGP 6809 is a promising new agent for clinical trials, especially for large bowel and epidermoid lung cancer."( CGP 6809--a new nitrosoureido-sugar derivative with activity in human tumor xenografts.
Fiebig, HH; Löhr, GW; Widmer, KH; Winterhalter, BR, 1989)		2.44
"CGP 6809 is a water-soluble nitrosourea derivative with quite distinct chemical and biological properties as compared with the well-known representatives of this class of compounds. "( CGP 6809, a sugar-containing nitrosourea derivative: pharmacological and physicochemical properties.
Kanter, PM; Matter, A; Müller, M; Schieweck, K; Schmidt-Ruppin, KH; Stanek, J, 1989)		3.16
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (6)

TimeframeStudies, This Drug (%)All Drugs %
pre-19906 (100.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (16.67%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (83.33%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
1,2-dimethylhydrazine
1,2-Dimethylhydrazine: A DNA alkylating agent that has been shown to be a potent carcinogen and is widely used to induce colon tumors in experimental animals.. 1,2-dimethylhydrazine : A member of the class of hydrazines that is hydrazine in which one of the hydrogens attached to each nitrogen is replaced by a methyl group. A powerful DNA alkylating agent and carcinogen, it is used to induce colon cancer in laboratory rats and mice.		6.9610hydrazinesalkylating agent;
carcinogenic agent
fluorouracil
Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.. 5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.		6.9610nucleobase analogue;
organofluorine compound		antimetabolite;
antineoplastic agent;
environmental contaminant;
immunosuppressive agent;
radiosensitizing agent;
xenobiotic
tegafur
[no description available]		1.9610organohalogen compound;
pyrimidines
dimethylnitrosamine
Dimethylnitrosamine: A nitrosamine derivative with alkylating, carcinogenic, and mutagenic properties. It causes serious liver damage and is a hepatocarcinogen in rodents.		1.9610nitrosaminegeroprotector;
mutagen
methyl(acetoxymethyl)nitrosamine
methyl(acetoxymethyl)nitrosamine: RN given refers to parent cpd; structure in seventh source		1.9610
dimethylhydrazines
Dimethylhydrazines: Hydrazines substituted with two methyl groups in any position.		1.9610
1-(2-(2-(4-pyridyl)-2-imidazoline-1-yl)ethyl)-3-(4-carboxyphenyl)urea
1-(2-(2-(4-pyridyl)-2-imidazoline-1-yl)ethyl)-3-(4-carboxyphenyl)urea: RN given refers to parent cpd; structure in first source		1.9610
ConditionIndicatedRelationship StrengthStudiesTrials
Cancer of Colon
[description not available]		01.9610
Experimental Neoplasms
[description not available]		02.3720
Colonic Neoplasms
Tumors or cancer of the COLON.		01.9610
Benign Neoplasms
[description not available]		04.0531
Neoplasms
New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.		04.0531
Experimental Leukemia
[description not available]		01.9710
Emesis
[description not available]		03.3511
Nausea
An unpleasant sensation in the stomach usually accompanied by the urge to vomit. Common causes are early pregnancy, sea and motion sickness, emotional stress, intense pain, food poisoning, and various enteroviruses.		03.3511
Vomiting
The forcible expulsion of the contents of the STOMACH through the MOUTH.		03.3511
Alloxan Diabetes
[description not available]		01.9610
Leukemia L 1210
[description not available]		01.9610
Cancer of Lung
[description not available]		01.9610
Malignant Melanoma
[description not available]		01.9610
Lung Neoplasms
Tumors or cancer of the LUNG.		01.9610
Melanoma
A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445)		01.9610